Abstract: The disclosure provides a plurality of nucleic acid sequences comprising multiple variants of a reference sequence. The disclosure further provides plasmids, cells, methods and kits comprising the same.

Abstract: The disclosure provides a plurality of nucleic acid sequences comprising multiple variants of a reference sequence. The disclosure further provides plasmids, cells, methods and kits comprising the same.

Abstract: The disclosure provides a plurality of nucleic acid sequences comprising multiple variants of a reference sequence. The disclosure further provides plasmids, cells, methods and kits comprising the same.

Abstract: Systems and methods are used to provide an online tool for clinical laboratories to monitor Next-Generation Sequencing (NGS) workflow using Quality Control (QC) material that can be used for multiple assays. The tool utilizes a highly multiplexed QC with NGS assays that detect somatic mutations. The control provides a common QC material that can be used across laboratories with different NGS instrument platforms, assays and bioinformatics pipelines to test precision and detect analytical deviations that may arise from reagent and instrument variation.

Abstract: The disclosure provides a plurality of nucleic acid sequences comprising multiple variants of a reference sequence. The disclosure further provides plasmids, cells, methods and kits comprising the same.

Abstract: The disclosure provides a plurality of nucleic acid sequences comprising multiple variants of a reference sequence. The disclosure further provides plasmids, cells, methods and kits comprising the same.

Abstract: Methods for treating neoplasms, by administering oncolytic viruses to a neoplasm having activated PP2A-like or Rac activities, are disclosed. The virus is administered so that it ultimately directly contacts target cancer cells. Combinations of more than one type and/or strain of oncolytic viruses can be used. Of particular interest is the use of reovirus.